Rui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rui Wang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Yue Wu
Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University
4 shared publicationsShanshan Zhang
Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University
3 shared publicationsYang Liu
Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University
3 shared publicationsYufo Chen
Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University
3 shared publications- Yumei Li
Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
3 shared publications Guiyun Zhang
Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University
2 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1863777
Development and internal validation of a task-conditioned multimodal radiology–pathology model for breast cancer staging and biomarker profiling: a retrospective cohort study
Objectives: To retrospectively develop and evaluate a task-conditioned multimodal artificial intelligence framework, in which a learned task embedding and modality-availability mask generate endpoint-specific weights over predefined radiology-only, pathology-only, and fusion experts, for breast cancer staging and biomarker profiling. Methods: We retrospectively assembled a cohort of 923 patients with paired radiology and pathology data. Nine tasks included TNM components [tumor extent (T), nodal involvement (N), and distant metastasis (M)], clinical stage, histological grade, and estrogen receptor, progesterone receptor, HER2, and Ki-67 status. Five convolutional neural network backbones were benchmarked for each modality. Task-specific models were selected by validation AUROC, and a late-fusion transformer was used for paired data. We further evaluated learned MoE gating, task-conditioned MoE routing with task embeddings and modality-availability masks, missing-modality robustness, and paired-bootstrap AUROC comparisons. An independent external cohort assessed feasibility for mammography-based pathological complete response and pathology-based triple-negative breast cancer (TNBC) prediction. Results: Best single-modality models achieved AUROCs ranging from 0.606 to 0.990 across tasks, with an AUROC of 0.990 observed for M staging and strong performance observed for histological grade (AUROC, 0.949; accuracy, 0.908) and HER2 status (AUROC, 0.810; accuracy, 0.762). Fixed late fusion improved the mean AUROC from 0.813 to 0.826. Learned MoE gating and task-conditioned MoE further improved mean AUROC to 0.830 and 0.834, respectively. Task-conditioned MoE improved mean AUROC by 0.009 over fixed late fusion (95% CI, 0.005–0.013; P = 0.011) and by 0.021 over the best single-modality expert. Under 70% random missing-modality simulation, task-conditioned MoE outperformed fixed fusion with zero imputation by 0.067 mean AUROC. In external feasibility analyses, the mammography-based pCR model achieved an AUROC of 0.758, and the pathology-based triple-negative breast cancer model achieved an AUROC of 0.872. Conclusion: OmniBreast demonstrated the feasibility of task-conditioned radiology-only, pathology-only, and fused prediction in the internal nine-task benchmark. The external analyses provided preliminary support for feasibility on two related endpoint-extension tasks but did not establish generalizability across the nine primary tasks; multicenter external validation and prospective clinical evaluation remain necessary.
- 21 August 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1863777
Open AccessDevelopment and internal validation of a task-conditioned multimodal radiology–pathology model for breast cancer staging and biomarker profiling: a retrospective cohort study
Objectives: To retrospectively develop and evaluate a task-conditioned multimodal artificial intelligence framework, in which a learned task embedding and modality-availability mask generate endpoint-specific weights over predefined radiology-only, pathology-only, and fusion experts, for breast cancer staging and biomarker profiling. Methods: We retrospectively assembled a cohort of 923 patients with paired radiology and pathology data. Nine tasks included TNM components [tumor extent (T), nodal involvement (N), and distant metastasis (M)], clinical stage, histological grade, and estrogen receptor, progesterone receptor, HER2, and Ki-67 status. Five convolutional neural network backbones were benchmarked for each modality. Task-specific models were selected by validation AUROC, and a late-fusion transformer was used for paired data. We further evaluated learned MoE gating, task-conditioned MoE routing with task embeddings and modality-availability masks, missing-modality robustness, and paired-bootstrap AUROC comparisons. An independent external cohort assessed feasibility for mammography-based pathological complete response and pathology-based triple-negative breast cancer (TNBC) prediction. Results: Best single-modality models achieved AUROCs ranging from 0.606 to 0.990 across tasks, with an AUROC of 0.990 observed for M staging and strong performance observed for histological grade (AUROC, 0.949; accuracy, 0.908) and HER2 status (AUROC, 0.810; accuracy, 0.762). Fixed late fusion improved the mean AUROC from 0.813 to 0.826. Learned MoE gating and task-conditioned MoE further improved mean AUROC to 0.830 and 0.834, respectively. Task-conditioned MoE improved mean AUROC by 0.009 over fixed late fusion (95% CI, 0.005–0.013; P = 0.011) and by 0.021 over the best single-modality expert. Under 70% random missing-modality simulation, task-conditioned MoE outperformed fixed fusion with zero imputation by 0.067 mean AUROC. In external feasibility analyses, the mammography-based pCR model achieved an AUROC of 0.758, and the pathology-based triple-negative breast cancer model achieved an AUROC of 0.872. Conclusion: OmniBreast demonstrated the feasibility of task-conditioned radiology-only, pathology-only, and fused prediction in the internal nine-task benchmark. The external analyses provided preliminary support for feasibility on two related endpoint-extension tasks but did not establish generalizability across the nine primary tasks; multicenter external validation and prospective clinical evaluation remain necessary.
- Open Access
- 28 January 2026
- Published by Springer Nature in Research Square
An agentic multimodal AI framework for end-to-end breast cancer staging and biomarker profiling
Background Breast cancer care spans screening, diagnosis and molecular stratification, yet most AI systems remain siloed into single tasks and single modalities. A unified, agentic system that can invoke specialized models across modalities could streamline end-to-end decision support. Methods We curated a cohort of 923 patients with paired radiology and pathology data and trained five CNN backbones (ResNet, DenseNet, EfficientNet, RegNet and MobileNetV3) for nine clinically relevant tasks, including T/N/M and clinical staging, histological grade, ER/PR/HER2 status and Ki-67 expression. We further implemented a late-fusion transformer and an orchestration layer that selects the appropriate single-modality or fused model per query, and evaluated performance using AUROC, accuracy and F1-score. Results Across tasks, the best single-modality models achieved AUROCs from 0.606 to 0.990, with strong performance for histological grade (AUROC 0.950; accuracy 0.909) and HER2 status (AUROC 0.810; accuracy 0.762). Multimodal fusion consistently improved discrimination over the best single modality (mean ΔAUROC 0.016), reaching AUROC 0.964 and accuracy 0.924 for grade, AUROC 0.831 for HER2 and AUROC 0.806 for N staging. Conclusion Together, these results show that agent-guided multimodal modelling can deliver robust, task-adaptive predictions spanning staging and biomarker profiling within a single framework. By enabling modular deployment—from screening-time risk triage to pathology-informed stratification—this approach provides a practical foundation for scalable, clinically integrated breast cancer decision support.
- 28 January 2026
- Published by Springer Nature in Research Square
Open AccessAn agentic multimodal AI framework for end-to-end breast cancer staging and biomarker profiling
Background Breast cancer care spans screening, diagnosis and molecular stratification, yet most AI systems remain siloed into single tasks and single modalities. A unified, agentic system that can invoke specialized models across modalities could streamline end-to-end decision support. Methods We curated a cohort of 923 patients with paired radiology and pathology data and trained five CNN backbones (ResNet, DenseNet, EfficientNet, RegNet and MobileNetV3) for nine clinically relevant tasks, including T/N/M and clinical staging, histological grade, ER/PR/HER2 status and Ki-67 expression. We further implemented a late-fusion transformer and an orchestration layer that selects the appropriate single-modality or fused model per query, and evaluated performance using AUROC, accuracy and F1-score. Results Across tasks, the best single-modality models achieved AUROCs from 0.606 to 0.990, with strong performance for histological grade (AUROC 0.950; accuracy 0.909) and HER2 status (AUROC 0.810; accuracy 0.762). Multimodal fusion consistently improved discrimination over the best single modality (mean ΔAUROC 0.016), reaching AUROC 0.964 and accuracy 0.924 for grade, AUROC 0.831 for HER2 and AUROC 0.806 for N staging. Conclusion Together, these results show that agent-guided multimodal modelling can deliver robust, task-adaptive predictions spanning staging and biomarker profiling within a single framework. By enabling modular deployment—from screening-time risk triage to pathology-informed stratification—this approach provides a practical foundation for scalable, clinically integrated breast cancer decision support.
- Open Access
- 18 April 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study
Objective This study aims to assess the efficacy and safety of RC48 in combination with PD-1 inhibitors for patients diagnosed with locally advanced or metastatic urothelial carcinoma (mUC). Methods A retrospective analysis was performed on clinical data from 53 patients with locally advanced or metastatic bladder cancer, who were treated at the First Affiliated Hospital of Bengbu Medical College between January 2023 and December 2023. The cohort was stratified into two groups: the RC48 combined immunotherapy group (RC48 + PD-1, n = 27) and the conventional chemotherapy group (gemcitabine and cisplatin regimen, GP, n = 26). Results The RC48 + PD-1 group demonstrated significantly higher objective response rates (ORR) and median progression-free survival (PFS) compared to the chemotherapy group (P < 0.05). Notably, the incidence of grade 3 or higher adverse events was elevated in the chemotherapy cohort, predominantly due to hematologic toxicities, with no treatment-related fatalities reported. In contrast, the RC48 combined PD-1 group primarily experienced immune-related adverse events, without any incidents of grade 3 or higher adverse effects or treatment-related deaths. Conclusion The combination of RC48 and PD-1 inhibitors exhibits promising antitumor activity and a manageable safety profile in patients with locally advanced or metastatic UC.
- 18 April 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-14
Open AccessEfficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study
Objective This study aims to assess the efficacy and safety of RC48 in combination with PD-1 inhibitors for patients diagnosed with locally advanced or metastatic urothelial carcinoma (mUC). Methods A retrospective analysis was performed on clinical data from 53 patients with locally advanced or metastatic bladder cancer, who were treated at the First Affiliated Hospital of Bengbu Medical College between January 2023 and December 2023. The cohort was stratified into two groups: the RC48 combined immunotherapy group (RC48 + PD-1, n = 27) and the conventional chemotherapy group (gemcitabine and cisplatin regimen, GP, n = 26). Results The RC48 + PD-1 group demonstrated significantly higher objective response rates (ORR) and median progression-free survival (PFS) compared to the chemotherapy group (P < 0.05). Notably, the incidence of grade 3 or higher adverse events was elevated in the chemotherapy cohort, predominantly due to hematologic toxicities, with no treatment-related fatalities reported. In contrast, the RC48 combined PD-1 group primarily experienced immune-related adverse events, without any incidents of grade 3 or higher adverse effects or treatment-related deaths. Conclusion The combination of RC48 and PD-1 inhibitors exhibits promising antitumor activity and a manageable safety profile in patients with locally advanced or metastatic UC.
- Open Access
- 9 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Evaluation of the efficacy and predictive indicators of PD- 1 inhibitors combined with chemotherapy in advanced pancreatic cancer
Patients with advanced pancreatic ductal adenocarcinoma (PDAC) generally face a poor prognosis and limited therapeutic options. This study aims to evaluate the clinical efficacy of combining PD- 1 inhibitors with chemotherapy as a first-line treatment for advanced PDAC, and to explore the correlation between various clinical parameters and treatment outcomes.This retrospective study analyzed the clinical data of 57 patients with advanced PDAC treated at the First Affiliated Hospital of Bengbu Medical University from January 2022 and June 2024. Patients were allocate into the two groups: the chemotherapy-alone group (29 cases) (CT), which received either the AG regimen or the mFOLFIRINOX regimen, and the imimmunotherapy plus chemotherapy group (28 cases) (ICT), which received the AG regimen or mFOLFIRINOX regimen in combination with PD- 1 inhibitors.The study compared progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions between the two groups. Additionally, it analyzed the correlation between various clinical indicators and their dynamic changes over time in relation to treatment outcomes. Kaplan-Meier curves were plotted for survival analysis, and log-rank tests assessed PFS and OS differences.Univariate and multivariate Cox regression analyses identified independent risk factors for prognosis, while logistic regression assessed the correlation between these factors and treatment response.The median PFS and OS in immunotherapy plus chemotherapy group were significantly superior to those in the chemotherapy-alone group (PFS: 7.3 vs. 5.8 months, P = 0.005; OS: 12 vs. 10.2 months, P = 0.031). The ORR in the group receive immunotherapy combined with chemotherapy was also significantly higher compared to the group treated with chemotherapy alone (42.86% vs. 17.24%, P = 0.03). No significant differences were observed in the incidence or severity of treatment-related adverse events (TRAEs) and immunotherapy-related adverse events (irAEs) between the CT and ICTgroups (any grade: 93.10% vs. 96.45%, P = 0.574; grade 3 or 4: 31.3% vs. 28.57%, P = 0.839). Patients without liver metastasis, without diabetes, or those who experience a increase in SOD levels following treatment may constitute an advantageous population for immune combination therapy. In conclusion, chemotherapy combined with PD- 1 inhibitors demonstrated favorable safety and tolerability, and significantly improved PFS, OS, and ORR compared to chemotherapy alone.
- 9 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessEvaluation of the efficacy and predictive indicators of PD- 1 inhibitors combined with chemotherapy in advanced pancreatic cancer
Patients with advanced pancreatic ductal adenocarcinoma (PDAC) generally face a poor prognosis and limited therapeutic options. This study aims to evaluate the clinical efficacy of combining PD- 1 inhibitors with chemotherapy as a first-line treatment for advanced PDAC, and to explore the correlation between various clinical parameters and treatment outcomes.This retrospective study analyzed the clinical data of 57 patients with advanced PDAC treated at the First Affiliated Hospital of Bengbu Medical University from January 2022 and June 2024. Patients were allocate into the two groups: the chemotherapy-alone group (29 cases) (CT), which received either the AG regimen or the mFOLFIRINOX regimen, and the imimmunotherapy plus chemotherapy group (28 cases) (ICT), which received the AG regimen or mFOLFIRINOX regimen in combination with PD- 1 inhibitors.The study compared progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions between the two groups. Additionally, it analyzed the correlation between various clinical indicators and their dynamic changes over time in relation to treatment outcomes. Kaplan-Meier curves were plotted for survival analysis, and log-rank tests assessed PFS and OS differences.Univariate and multivariate Cox regression analyses identified independent risk factors for prognosis, while logistic regression assessed the correlation between these factors and treatment response.The median PFS and OS in immunotherapy plus chemotherapy group were significantly superior to those in the chemotherapy-alone group (PFS: 7.3 vs. 5.8 months, P = 0.005; OS: 12 vs. 10.2 months, P = 0.031). The ORR in the group receive immunotherapy combined with chemotherapy was also significantly higher compared to the group treated with chemotherapy alone (42.86% vs. 17.24%, P = 0.03). No significant differences were observed in the incidence or severity of treatment-related adverse events (TRAEs) and immunotherapy-related adverse events (irAEs) between the CT and ICTgroups (any grade: 93.10% vs. 96.45%, P = 0.574; grade 3 or 4: 31.3% vs. 28.57%, P = 0.839). Patients without liver metastasis, without diabetes, or those who experience a increase in SOD levels following treatment may constitute an advantageous population for immune combination therapy. In conclusion, chemotherapy combined with PD- 1 inhibitors demonstrated favorable safety and tolerability, and significantly improved PFS, OS, and ORR compared to chemotherapy alone.
- Open Access
Combination therapy with alisertib enhances the anti-tumor immunity induced by a liver cancer vaccine
- Open Access
- 25 December 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 25 (7) , 1528-1539
Mechanistic insights into Y-Box binding protein-1 mediated regulation of lipid metabolism and oxidative stress in NAFLD via INHBE/TNF-β pathway
Nonalcoholic fatty liver disease (NAFLD) is a prevalent liver disorder that has emerged as a significant public health concern. This study aimed to investigate the mechanisms by which Y-box binding protein-1 (YB1) knockdown influences lipid metabolism and oxidative stress in palmitic acid (PA)-induced NAFLD LO2 cells. The expression of YB1 was analyzed using the GSE89632 dataset from the Gene Expression Omnibus (GEO) database. RNA sequencing was performed, followed by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, and protein-protein interaction (PPI) network analyses to identify differentially expressed genes (DEGs). Quantitative real-time PCR (QRT-PCR), Western blotting, flow cytometry, and various biochemical assays were used to evaluate gene expression, lipid accumulation, and oxidative stress. Our results demonstrated that YB1 is highly expressed in NAFLD. RNA sequencing revealed 798 DEGs between the shCtrl and shYB1 groups, with 190 genes upregulated and 608 genes downregulated. Notably, we observed an increase in Inhibin beta E (INHBE) expression, while EGR1, GDF15, NUPR1, and FOSB were decreased in NAFLD LO2 cells. YB1 knockdown, particularly when combined with INHBE suppression, significantly enhanced cell viability, improved lipid metabolism, and reduced reactive oxygen species (ROS) accumulation and malondialdehyde (MDA) content. The downstream mechanism was primarily associated with TNF-β signaling. Specifically, we observed decreased levels of TGF-β1, p-Smad2, and p-Smad3 following YB1 and INHBE knockdown. Furthermore, INHBE overexpression reversed the beneficial effects induced by YB1 knockdown. In conclusion, YB1 knockdown improves lipid metabolism and reduces oxidative stress in NAFLD LO2 cells, largely through the INHBE/TNF-β signaling pathway. These findings provide valuable insights into novel therapeutic strategies for managing NAFLD.
- 25 December 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 25 (7) , 1528-1539
Open AccessMechanistic insights into Y-Box binding protein-1 mediated regulation of lipid metabolism and oxidative stress in NAFLD via INHBE/TNF-β pathway
Nonalcoholic fatty liver disease (NAFLD) is a prevalent liver disorder that has emerged as a significant public health concern. This study aimed to investigate the mechanisms by which Y-box binding protein-1 (YB1) knockdown influences lipid metabolism and oxidative stress in palmitic acid (PA)-induced NAFLD LO2 cells. The expression of YB1 was analyzed using the GSE89632 dataset from the Gene Expression Omnibus (GEO) database. RNA sequencing was performed, followed by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, and protein-protein interaction (PPI) network analyses to identify differentially expressed genes (DEGs). Quantitative real-time PCR (QRT-PCR), Western blotting, flow cytometry, and various biochemical assays were used to evaluate gene expression, lipid accumulation, and oxidative stress. Our results demonstrated that YB1 is highly expressed in NAFLD. RNA sequencing revealed 798 DEGs between the shCtrl and shYB1 groups, with 190 genes upregulated and 608 genes downregulated. Notably, we observed an increase in Inhibin beta E (INHBE) expression, while EGR1, GDF15, NUPR1, and FOSB were decreased in NAFLD LO2 cells. YB1 knockdown, particularly when combined with INHBE suppression, significantly enhanced cell viability, improved lipid metabolism, and reduced reactive oxygen species (ROS) accumulation and malondialdehyde (MDA) content. The downstream mechanism was primarily associated with TNF-β signaling. Specifically, we observed decreased levels of TGF-β1, p-Smad2, and p-Smad3 following YB1 and INHBE knockdown. Furthermore, INHBE overexpression reversed the beneficial effects induced by YB1 knockdown. In conclusion, YB1 knockdown improves lipid metabolism and reduces oxidative stress in NAFLD LO2 cells, largely through the INHBE/TNF-β signaling pathway. These findings provide valuable insights into novel therapeutic strategies for managing NAFLD.
- Open Access
- 8 August 2024
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 18 (8) , e13819
Evaluation of Efficacy and Safety in First‐Line Treatment Methods for Extensive‐Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy
Background: Small cell lung cancer (SCLC) is a highly aggressive tumor with limited effectiveness in its standard chemotherapy treatment. Targeted antiangiogenic therapy and immune checkpoint inhibitors (ICIs) have demonstrated potential as alternative treatments for extensive‐stage SCLC (ES‐SCLC). However, there is insufficient comparative evidence available to determine the optimal first‐line treatment option between ICIs plus chemotherapy and targeted antiangiogenic therapy plus chemotherapy.Objective: This study is aimed at analyzing clinical data from ES‐SCLC patients treated at the First Affiliated Hospital of Bengbu Medical College between June 2021 and June 2023. The study compared the efficacy and safety of three first‐line treatment regimens: standard chemotherapy, antiangiogenic therapy combined with chemotherapy, and immune combination therapy.Methods: Patients who met the inclusion criteria were divided into three groups: chemotherapy, immune combination therapy, and antiangiogenic therapy combined with chemotherapy. The study collected data on clinical characteristics, treatment regimens, and adverse reactions. The analysis included objective response rate (ORR), duration of response (DoR), disease control rate (DCR), progression‐free survival (PFS), and treatment safety.Results: A total of 101 patients were included in the study, with 49 receiving chemotherapy alone, 19 receiving antiangiogenic therapy, and 33 receiving immune combination therapy. The ORRs were 78.9% for antiangiogenic therapy, 72.7% for immune combination therapy, and 42.9% for chemotherapy alone. The median PFS was 8.0 months for antiangiogenic therapy, 7.8 months for immune combination therapy, and 5.2 months for chemotherapy alone. Both combination therapy groups demonstrated superior efficacy compared to chemotherapy alone.Conclusion: Targeted combined chemotherapy and immune combination chemotherapy showed superior efficacy as first‐line treatments for ES‐SCLC compared to chemotherapy alone, with manageable adverse reactions.
- 8 August 2024
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 18 (8) , e13819
Open AccessEvaluation of Efficacy and Safety in First‐Line Treatment Methods for Extensive‐Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy
Background: Small cell lung cancer (SCLC) is a highly aggressive tumor with limited effectiveness in its standard chemotherapy treatment. Targeted antiangiogenic therapy and immune checkpoint inhibitors (ICIs) have demonstrated potential as alternative treatments for extensive‐stage SCLC (ES‐SCLC). However, there is insufficient comparative evidence available to determine the optimal first‐line treatment option between ICIs plus chemotherapy and targeted antiangiogenic therapy plus chemotherapy.Objective: This study is aimed at analyzing clinical data from ES‐SCLC patients treated at the First Affiliated Hospital of Bengbu Medical College between June 2021 and June 2023. The study compared the efficacy and safety of three first‐line treatment regimens: standard chemotherapy, antiangiogenic therapy combined with chemotherapy, and immune combination therapy.Methods: Patients who met the inclusion criteria were divided into three groups: chemotherapy, immune combination therapy, and antiangiogenic therapy combined with chemotherapy. The study collected data on clinical characteristics, treatment regimens, and adverse reactions. The analysis included objective response rate (ORR), duration of response (DoR), disease control rate (DCR), progression‐free survival (PFS), and treatment safety.Results: A total of 101 patients were included in the study, with 49 receiving chemotherapy alone, 19 receiving antiangiogenic therapy, and 33 receiving immune combination therapy. The ORRs were 78.9% for antiangiogenic therapy, 72.7% for immune combination therapy, and 42.9% for chemotherapy alone. The median PFS was 8.0 months for antiangiogenic therapy, 7.8 months for immune combination therapy, and 5.2 months for chemotherapy alone. Both combination therapy groups demonstrated superior efficacy compared to chemotherapy alone.Conclusion: Targeted combined chemotherapy and immune combination chemotherapy showed superior efficacy as first‐line treatments for ES‐SCLC compared to chemotherapy alone, with manageable adverse reactions.
- Open Access
- 1 January 2021
- Published by SAGE Publications in European Journal of Inflammation
- Vol. 19
Rapamycin-induced M2 macrophage autophagy promotes the migration and invasion of bladder cancer cells via increased IL-10 secretion
Intrduction: Rapamycin is an mTOR inhibitor and a prominent inducer of autophagy in cancer cells and tumor interstitial cells. Macrophages are the primary type of immune cells observed in the tumor microenvironment and serve varying roles in the progression of cancer by polarizing into distinct phenotypes. However, whether rapamycin-induced macrophage autophagy influences bladder cancer remains unclear. Methods: THP-1 cells were successfully polarized into M1 or M2 macrophages, which were identified by detecting CD86 (M1) or CD206 (M2) expressions using flow cytometry and measuring M1/M2-related mRNA expressions using reverse transcription-quantitative PCR. Rapamycin was employed for inducing autophagy, and then the influences of enhanced autophagic M1 and M2 macrophages on migration and invasion of bladder cancer cells were confirmed by wound healing and Transwell assay in the co-culture model. Furthermore, the gene and protein expressions of IL-10 and the underlying role are still unclear. Results: Rapamycin significantly increased autophagy levels in M1 and M2 macrophages, while only autophagy-enhanced M2 macrophages facilitated the migration and invasion of bladder cancer cells. Furthermore, rapamycin increased IL-10 secretion from M2 macrophages, which mediated the effects of M2 macrophages on migration and invasion of bladder cancer. Conclusion: Rapamycin induces M2 macrophage autophagy and promotes the migration and invasion of bladder cancer by increasing IL-10 secretion, suggesting that M2 macrophage autophagy is an underlying target of rapamycin in treating bladder cancer.
- 1 January 2021
- Published by SAGE Publications in European Journal of Inflammation
- Vol. 19
Open AccessRapamycin-induced M2 macrophage autophagy promotes the migration and invasion of bladder cancer cells via increased IL-10 secretion
Intrduction: Rapamycin is an mTOR inhibitor and a prominent inducer of autophagy in cancer cells and tumor interstitial cells. Macrophages are the primary type of immune cells observed in the tumor microenvironment and serve varying roles in the progression of cancer by polarizing into distinct phenotypes. However, whether rapamycin-induced macrophage autophagy influences bladder cancer remains unclear. Methods: THP-1 cells were successfully polarized into M1 or M2 macrophages, which were identified by detecting CD86 (M1) or CD206 (M2) expressions using flow cytometry and measuring M1/M2-related mRNA expressions using reverse transcription-quantitative PCR. Rapamycin was employed for inducing autophagy, and then the influences of enhanced autophagic M1 and M2 macrophages on migration and invasion of bladder cancer cells were confirmed by wound healing and Transwell assay in the co-culture model. Furthermore, the gene and protein expressions of IL-10 and the underlying role are still unclear. Results: Rapamycin significantly increased autophagy levels in M1 and M2 macrophages, while only autophagy-enhanced M2 macrophages facilitated the migration and invasion of bladder cancer cells. Furthermore, rapamycin increased IL-10 secretion from M2 macrophages, which mediated the effects of M2 macrophages on migration and invasion of bladder cancer. Conclusion: Rapamycin induces M2 macrophage autophagy and promotes the migration and invasion of bladder cancer by increasing IL-10 secretion, suggesting that M2 macrophage autophagy is an underlying target of rapamycin in treating bladder cancer.
- Open Access
- 22 March 2018
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 37 (1) , 65
PHD-finger domain protein 5A functions as a novel oncoprotein in lung adenocarcinoma
Background: PHD-finger domain protein 5A (PHF5A) is a highly conserved small transcriptional regulator also involved in pre-mRNA splicing; however, its biological functions and molecular mechanisms in non-small cell lung cancer (NSCLC) have not yet been investigated. The purpose of this study was to determine the functional relevance and therapeutic potential of PHF5A in lung adenocarcinoma (LAC). Methods: The expression of PHF5A in LAC tissues and adjacent non-tumor (ANT) tissues was investigated using immunohistochemistry of a tissue microarray, qRT-PCR, western blot and bioinformatics. The function of PHF5A was determined using several in vitro assays and also in vivo assay by lentiviral vector-mediated PHF5A depletion in LAC cell lines. Results: PHF5A was highly upregulated in LAC tissues compared with the ANT counterparts, and closely associated with tumor progression and poor patient prognosis. These results were further confirmed by findings of the TCGA database. Moreover, functional studies demonstrated that PHF5A knockdown not only resulted in reduced cell proliferation, increased cell apoptosis, and cell cycle arrest, but also suppressed migration and invasion in LAC cells. PHF5A silencing was also found to inhibit LAC tumor growth in nude mice. Microarray and bioinformatics analyses revealed that PHF5A depletion led to dysregulation of multiple tumor signaling pathways; selected factors in key signaling pathways were verified in vitro. Conclusions: The data suggest for the first time that PHF5A is an oncoprotein that contributes to LAC progression by regulating multiple signaling pathways, and may constitute a prognostic factor and potential new therapeutic target in NSCLC.
- 22 March 2018
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 37 (1) , 65
Open AccessPHD-finger domain protein 5A functions as a novel oncoprotein in lung adenocarcinoma
Background: PHD-finger domain protein 5A (PHF5A) is a highly conserved small transcriptional regulator also involved in pre-mRNA splicing; however, its biological functions and molecular mechanisms in non-small cell lung cancer (NSCLC) have not yet been investigated. The purpose of this study was to determine the functional relevance and therapeutic potential of PHF5A in lung adenocarcinoma (LAC). Methods: The expression of PHF5A in LAC tissues and adjacent non-tumor (ANT) tissues was investigated using immunohistochemistry of a tissue microarray, qRT-PCR, western blot and bioinformatics. The function of PHF5A was determined using several in vitro assays and also in vivo assay by lentiviral vector-mediated PHF5A depletion in LAC cell lines. Results: PHF5A was highly upregulated in LAC tissues compared with the ANT counterparts, and closely associated with tumor progression and poor patient prognosis. These results were further confirmed by findings of the TCGA database. Moreover, functional studies demonstrated that PHF5A knockdown not only resulted in reduced cell proliferation, increased cell apoptosis, and cell cycle arrest, but also suppressed migration and invasion in LAC cells. PHF5A silencing was also found to inhibit LAC tumor growth in nude mice. Microarray and bioinformatics analyses revealed that PHF5A depletion led to dysregulation of multiple tumor signaling pathways; selected factors in key signaling pathways were verified in vitro. Conclusions: The data suggest for the first time that PHF5A is an oncoprotein that contributes to LAC progression by regulating multiple signaling pathways, and may constitute a prognostic factor and potential new therapeutic target in NSCLC.
- Open Access
- 1 April 2016
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 12, 909-916
Olig1 expression pattern in neural cells during rat spinal cord development
Purpose: Our purpose was to systematically investigate the expression pattern and role of Olig1 in neural cells during rat spinal cord development. Animals and methods: Spinal cord tissues were dissected from Sprague–Dawley rats at embryonic day 14.5 (E14.5) and E18.5, postnatal day 0 (P0), P3, P7, postnatal 2 weeks (P2W), P4W, and adults (more than 2 months after birth), respectively. The expression of Olig1 was determined by Western blot and immunostaining. To observe expression of Olig1 in different neural cell types, a double immunohistochemical staining was performed using antibodies against Olig1 with O4, ß-tubulin, glial fibrillary acidic protein (GFAP), and myelin basic protein, respectively. Results: The expression of Olig1 protein shows a significant level change in rat spinal cord at different developmental time points. Starting with E14.5, the expression gradually increased and peaked at E18.5. Olig1 decreased gradually from P3 and reached its lowest level on P7. However, interestingly, the Olig1 expression increased again from P2W, until adulthood. Olig1 was coexpressed with O4-positive oligodendrocyte progenitor cells (OPCs) and β-tubulin-positive neurons at all time points during development. Olig1 was also coexpressed transiently with GFAP-positive astrocytes at only E14.5. Olig1 was localized in the cytoplasm of O4- and β-tubulin-positive cells during the period from E14.5 to adult. Conclusion: The expression of Olig1 in OPCs and neurons at all time points during development and in astrocytes at E14.5 suggests that Olig1 may play an important role in the generation and maturation of specific neural cells during development of spinal cord. Our results contribute to understanding the mechanism underlying developmental regulation of neural cells by Olig1.
- 1 April 2016
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 12, 909-916
Open AccessOlig1 expression pattern in neural cells during rat spinal cord development
Purpose: Our purpose was to systematically investigate the expression pattern and role of Olig1 in neural cells during rat spinal cord development. Animals and methods: Spinal cord tissues were dissected from Sprague–Dawley rats at embryonic day 14.5 (E14.5) and E18.5, postnatal day 0 (P0), P3, P7, postnatal 2 weeks (P2W), P4W, and adults (more than 2 months after birth), respectively. The expression of Olig1 was determined by Western blot and immunostaining. To observe expression of Olig1 in different neural cell types, a double immunohistochemical staining was performed using antibodies against Olig1 with O4, ß-tubulin, glial fibrillary acidic protein (GFAP), and myelin basic protein, respectively. Results: The expression of Olig1 protein shows a significant level change in rat spinal cord at different developmental time points. Starting with E14.5, the expression gradually increased and peaked at E18.5. Olig1 decreased gradually from P3 and reached its lowest level on P7. However, interestingly, the Olig1 expression increased again from P2W, until adulthood. Olig1 was coexpressed with O4-positive oligodendrocyte progenitor cells (OPCs) and β-tubulin-positive neurons at all time points during development. Olig1 was also coexpressed transiently with GFAP-positive astrocytes at only E14.5. Olig1 was localized in the cytoplasm of O4- and β-tubulin-positive cells during the period from E14.5 to adult. Conclusion: The expression of Olig1 in OPCs and neurons at all time points during development and in astrocytes at E14.5 suggests that Olig1 may play an important role in the generation and maturation of specific neural cells during development of spinal cord. Our results contribute to understanding the mechanism underlying developmental regulation of neural cells by Olig1.